Biomarkers /
XRCC6
Overview
XRCC6 is altered in 1.12% of all cancers with colon adenocarcinoma, melanoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in XRCC6 are XRCC6 Mutation (0.98%), XRCC6 T334A (0.07%), XRCC6 Amplification (0.06%), XRCC6 Fusion (0.03%), and XRCC6 G191S (0.03%) [3].
Clinical Trials
Significance of XRCC6 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.